| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0-100.0% | $886K-62.0% | $2.3M-65.4% | $6.7M | $0 | $0-100.0% | $3.9M |
| Research and development | $171.7M+5.4% | $162.8M+81.9% | $89.5M+52.8% | $58.6M+2.6% | $57.1M-4.3% | $59.6M-7.7% | $64.6M+75.9% | $36.7M |
| General and administrative | $47.9M+4.7% | $45.8M+14.6% | $39.9M+40.0% | $28.5M+4.4% | $27.3M+25.1% | $21.8M+38.8% | $15.7M+24.6% | $12.6M |
| Acquired in-process research and development | $0 | $0-100.0% | $130.2M | $0 | $0 | — | — | — |
| Gain on sale of in-process research and development asset | -$10.0M | $0+100.0% | -$16.4M | $0 | $0 | — | — | — |
| Total operating expenses | $209.6M+0.5% | $208.6M-14.2% | $243.2M+179.2% | $87.1M+3.2% | $84.4M+3.6% | $81.5M+1.4% | $80.3M+62.8% | $49.4M |
| Loss from operations | -$209.6M-0.5% | -$208.6M+13.9% | -$242.3M-185.8% | -$84.8M-29.1% | -$65.6M+19.4% | -$81.5M-1.4% | -$80.3M-76.7% | -$45.5M |
| Interest income | $24.9M+16.8% | $21.3M+246.7% | $6.1M+634.4% | $837K+654.1% | $111K-81.3% | $593K-72.3% | $2.1M+82.8% | $1.2M |
| Other income (expense), net | $29.5M+242.2% | -$20.7M-8.3% | -$19.1M-273185.7% | -$7K+94.3% | -$122K-2340.0% | -$5K+92.1% | -$63K-10.5% | -$57K |
| Total other income (expense) | $54.3M+8972.5% | $599K+100.6% | -$96.5M-11728.1% | $830K+7645.5% | -$11K-101.9% | $588K-71.7% | $2.1M+86.5% | $1.1M |
| Loss before income tax expense | -$155.2M+25.4% | -$208.0M+38.6% | -$338.8M-303.6% | -$84.0M-27.9% | -$65.7M+18.8% | -$80.9M-3.4% | -$78.3M | — |
| Income tax benefit (expense) | $15K+129.4% | -$51K-296.2% | $26K-80.9% | $136K+196.5% | -$141K | $0 | $0 | — |
| Net loss | -$126.5M+15.4% | -$149.6M-57.6% | -$94.9M-13.2% | -$83.8M-27.4% | -$65.8M+18.7% | -$80.9M-3.4% | -$78.3M-76.5% | -$44.3M |
| Forward Contract Liability | ||||||||
| Change in fair value of forward contract liability | $0 | $0+100.0% | -$83.5M | $0 | $0 | — | — | — |
| Series A Non-Voting Convertible Preferred Stock | ||||||||
| Net loss per share, basic (in dollars per share) | -$1.98+37.7% | -$3.18+76.9% | -$13.76+99.9% | -$24860.00+0.6% | -$25020.00-1645952.6% | -$1.52 | — | — |
| Net loss per share, diluted (in dollars per share) | -$1.98+37.7% | -$3.18+76.9% | -$13.76+99.9% | -$24860.00+0.6% | -$25020.00-1645952.6% | -$1.52 | — | — |
| Weighted-average common shares outstanding, basic (in shares) | 64.1M+36.2% | 47.0M+581.9% | 6.9M-99.8% | 3.37B+28.2% | 2.63B-95.1% | 53.37B | — | — |
| Weighted-average common shares outstanding, diluted (in shares) | 64.1M+36.2% | 47.0M+581.9% | 6.9M-99.8% | 3.37B+28.2% | 2.63B-95.1% | 53.37B | — | — |
| Series B Non-Voting Convertible Preferred Stock | ||||||||
| Common Stock | ||||||||
| Development fee and royalty | ||||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.